Top 10 Trihexyphenidyl (Artane) Generic Manufacturers in India
The global market for Trihexyphenidyl, commonly known by its brand name Artane, is witnessing significant growth, particularly in India, which is a key player in the pharmaceutical industry. As of 2022, the Indian generics market was valued at approximately USD 20 billion, with a projected compound annual growth rate (CAGR) of 11% through 2026. The increasing prevalence of Parkinson’s disease and other movement disorders is driving demand for Trihexyphenidyl, making it essential to identify leading manufacturers of this crucial medication. Below is a list of the top 10 Trihexyphenidyl generic manufacturers in India.
1. Sun Pharmaceutical Industries Ltd.
Sun Pharma is one of the largest pharmaceutical companies in India, with a significant market share in the generic segment. The company produces Trihexyphenidyl with an annual production volume of over 200 million tablets. Sun Pharma’s extensive distribution network ensures wide availability and accessibility of its products.
2. Aurobindo Pharma Ltd.
Aurobindo Pharma is a major player in the Indian pharmaceutical market, with a strong focus on generic formulations. The company produces Trihexyphenidyl at a capacity of approximately 150 million tablets per year, contributing to a solid market share of around 8% in the neurology segment.
3. Mylan Pharmaceuticals Pvt Ltd.
Mylan, now part of Viatris, is known for its diverse portfolio of generic drugs, including Trihexyphenidyl. The company has a manufacturing capacity of over 100 million tablets annually and holds a significant position in the CNS (Central Nervous System) therapeutics market.
4. Cipla Ltd.
Cipla is a prominent pharmaceutical manufacturer in India, focusing on both branded and generic medications. With a production capacity for Trihexyphenidyl nearing 80 million tablets per year, Cipla maintains a strong standing in the market, supported by its robust research and development initiatives.
5. Dr. Reddy’s Laboratories Ltd.
Dr. Reddy’s is a well-established player in the Indian pharmaceutical industry, with a reputation for high-quality generics. The company produces Trihexyphenidyl with an estimated production volume of 60 million tablets annually, contributing to its significant market presence.
6. Zydus Cadila
Zydus Cadila is another key manufacturer in the Indian generics market, producing Trihexyphenidyl at an annual capacity of approximately 50 million tablets. The company’s extensive R&D capabilities support its competitive edge in the CNS segment.
7. Glenmark Pharmaceuticals Ltd.
Glenmark Pharmaceuticals has a strong footprint in the Indian market and is known for its generics. With a production capacity of around 40 million Trihexyphenidyl tablets per year, Glenmark is capitalizing on the growing demand within the neurology space.
8. Hetero Labs Ltd.
Hetero Labs specializes in manufacturing various generic medications, including Trihexyphenidyl. The company’s production volume is estimated at 30 million tablets annually, making it a notable contributor to the Indian generics landscape.
9. Alkem Laboratories Ltd.
Alkem Laboratories is recognized for its strong portfolio in therapeutic segments, including neurology. The company produces about 25 million tablets of Trihexyphenidyl each year, reflecting its commitment to addressing the needs of patients with movement disorders.
10. Torrent Pharmaceuticals Ltd.
Torrent Pharmaceuticals has established a significant presence in the Indian pharmaceutical market. The company produces Trihexyphenidyl with an annual capacity of approximately 20 million tablets, focusing on quality and affordability.
Insights
The Indian generics market continues to expand rapidly, driven by the increasing prevalence of neurological disorders and a growing aging population. As of 2023, the total market for CNS medications is projected to reach USD 10 billion in India, with Trihexyphenidyl playing a crucial role in this segment. The competition among manufacturers is intensifying, leading to innovations in formulation and cost-effective production methods. With regulatory support and increasing export opportunities, Indian manufacturers are well-positioned to meet both domestic and global demands for Trihexyphenidyl, ensuring that healthcare providers can offer effective treatment options for patients with movement disorders.
Related Analysis: View Previous Industry Report
